Posted: 18/06/2025
The corporate team at Penningtons Manches Cooper is advising SkinBioTherapeutics plc (AIM: SBTX) on a £4.6 million placing, subscription and a separate retail offer to existing shareholders through the Winterflood Retail Access Platform.
This is the fifth equity fundraising on AIM on which Penningtons Manches Cooper has advised long standing client SkinBioTherapeutics. Singer Capital Markets acted as nominated adviser and broker. The transaction is expected to close on 24 June 2025.
SkinBioTherapeutics is a life science company focused on skin health. On 16 June 2025, it announced that it had signed an exclusive UK commercial agreement with Superdrug Stores plc, one of the UK's leading beauty and health retailers, related to its AxisBiotix™ food supplements to alleviate the symptoms of inflammatory skin conditions.
The net proceeds of the fundraising will enable SkinBioTherapeutics to facilitate and support the agreement with Superdrug and provide additional working capital.
London-based corporate partner Seb Orton led on this transaction, with assistance from associate Jenny Wright.
© 2025 Penningtons Manches Cooper LLP.
All rights reserved.
Website design by Frontmedia / Dynamic Pear
Penningtons Manches Cooper LLP is a limited liability partnership registered in England and Wales with registered number OC311575 and is authorised and regulated by the Solicitors Regulation Authority under number 419867.
Return to news headlines 
